Skip to main content
v2026.11,986 entries · CC-BY 4.0

Editorial · CASRAI · Clinical research and clinical trials

Evotec wins $2.9 million Gates grant for stem-cell drug safety research

A new $2.9 million Gates Foundation grant extends Evotec human stem-cell drug safety research for another three years.

Published 17 Nov 2026· 5 minute read

Ask CASRAI · free to try

Ask about this story

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

CASRAI is the reference for research administration — bookmark it for the next question.

Evotec announced in Hamburg on November 16, 2026, that it had received a new $2.9 million Gates Foundation grant to extend human stem-cell research for early drug safety testing. The three-year renewal supports a platform used by global-health researchers to identify potential risks to fetal development before advancing drug candidates.

Renewal extends a global-health research platform

The company’s announcement says the award continues a project begun in 2023. The platform combines human induced pluripotent stem-cell models with screening at industrial scale. Its purpose is to identify possible developmental safety problems earlier in discovery and help researchers decide which candidates to pursue. The funding supports continued access for researchers working on global-health programmes.

Grafa’s November 16 report describes the award as a further three years of support for the same research platform. It reports that the initial collaboration screened more than 5,000 compounds across nine grantee programmes. Those figures describe the volume and reach of the earlier collaboration, providing a baseline for the renewed funding.

The collaboration began with a 2023 grant

Evotec’s December 19, 2023 announcement recorded an initial $2.5 million grant and the company’s entry into the Global Health Discovery Collaboratory. It described that network as bringing together researchers, centres of excellence and technology platforms to accelerate the discovery and translation of global-health interventions.

Under the original arrangement, Collaboratory members receiving foundation funding could use the platform at no extra cost. The company described multiple human cell-based model systems representing tissues affected by compounds that can disrupt fetal development. Automated imaging and image analysis supported assessment of those compounds in a high-throughput format. CASRAI’s induced pluripotent stem-cell guide explains the research platform underlying this type of model.

The 2023 document positioned the assay as an early way to reduce development risk and explicitly retained later-stage animal-study requirements. That distinction matters when research teams interpret the renewed grant: the original project was designed to improve earlier candidate selection within a broader safety programme.

Researchers are assessing compounds before clinical development

Grafa reports that the work identifies possible teratogenic effects, meaning risks to fetal development, before candidates move into clinical testing. It also places the assay within Evotec’s wider New Approach Methodologies portfolio, which includes more than 25 stem-cell-derived models, three-dimensional organoid systems and AI-supported disease modelling. The grant is tied to the developmental-safety platform within that broader research capability.

Independent German publication Dr. Web covered the renewal on November 16, connecting the stem-cell screening approach with the wider move toward human-relevant safety methods. Its analysis urges biotechnology companies and contract laboratories to ask how cell-model evidence will be used in safety dossiers and which additional studies regulators require. That is a practical question for university groups preparing to transfer a candidate into commercial development.

FDA policy supplies the regulatory context

The FDA’s Roadmap to Reducing Animal Testing in Preclinical Safety Studies, issued in April 2025, sets out a stepwise approach to using scientifically validated alternatives. It includes human-based in vitro systems, computational models and other methods intended to improve the relevance of safety assessment while reducing animal use. CASRAI’s definition of New Approach Methodologies explains this category.

The roadmap initially focuses on monoclonal antibodies, with expansion to other biological molecules and eventually new chemical entities and medical countermeasures. It also describes submitting NAM evidence alongside animal data to build regulatory experience, assessing pilot cases and monitoring outcomes. Its emphasis on validation gives research teams a specific framework for considering how an experimental model might contribute to a development dossier.

The document includes high-throughput screening with human cells among the approaches it discusses. For researchers, the relevant connection is the type of evidence such systems can generate and the process for validating its use. The ICH M3(R2) nonclinical safety guide provides background on planning nonclinical evidence across drug development.

Holbrook puts the emphasis on earlier decisions

Evotec chief scientific officer Joanna Holbrook said early identification of safety risks is important to advancing medicines for global-health priorities. In the November 16 announcement, she described the platform as helping researchers choose candidates and reduce the risk of expensive changes later in development. Her comments frame the renewal around research decisions and continued access to a shared capability.

What the renewal means for research offices

For universities collaborating on global-health drug discovery, the practical implication is continuity of a screening resource over another three years. Research offices discussing participation should establish the access arrangements for their specific programme and how the resulting evidence fits its development plan. The original agreement’s funded-member access model is useful context for those discussions, rather than a substitute for the terms of a current collaboration.

The renewal also illustrates a funding mechanism that supports a technology platform used across multiple grantee programmes. Researchers assessing the Gates Foundation’s research grant programmes can distinguish that shared infrastructure support from an award made directly to their own institution. The announced next stage is continued operation over the new three-year funding period.

Sources

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →